William Branchett

William Branchett is a mucosal immunologist working as a Research Fellow at The Francis Crick Institute since 2020, focusing on early immune responses to Mycobacterium tuberculosis and mucosal immunity regulation. His work bridges respiratory and intestinal immunology with direct implications for tuberculosis and inflammatory bowel disease.

His academic foundation includes:

• PhD in Immunology from Imperial College London (2018)
• MSc in Immunology from King's College London (2014)
• MBiolSci in Biochemistry and Microbiology from University of Sheffield (2013)

Branchett's research centers on cytokine-mediated immune regulation, particularly Type I Interferons, Interleukin-10, and TGF-β1 in mucosal tissues. He investigates how neutrophil swarming, T cell-macrophage interactions, and transcription factor networks (e.g., Blimp-1/c-Maf) influence disease outcomes in tuberculosis, asthma, and colitis. His methodology integrates transcriptomics, flow cytometry, and advanced genomic techniques through Crick's core facilities.

His eight publications (2019-2025) reveal an evolving focus from broad interferon networks to disease-specific mechanisms, with increasing emphasis on M. tuberculosis pathogenesis and mucosal repair pathways. Key journals include Nature Immunology, Journal of Experimental Medicine, and Nature Communications, highlighting translational relevance to human disease.

Scientific awards: No awards documented in source material.

Branchett operates within collaborative frameworks under Principal Investigator Anne O'Garra, utilizing multi-lab resources but with no student advisement or independent grant leadership indicated. His work likely contributes to larger Crick Institute-funded tuberculosis and mucosal immunity initiatives.

He is embedded in the Anne O'Garra laboratory ecosystem, leveraging Genomics, Bioinformatics, Flow Cytometry, and Experimental Histopathology facilities. Current projects involve cross-departmental teams studying neutrophil dynamics in TB and IL-10-mediated inflammation resolution, with future work expected to explore therapeutic targeting of mucosal immune checkpoints.